Mina Miljevic


Mina Miljevic


Washington, D.C. | 1900 K Street, NW, Washington, DC, United States of America 20006-1110
+1 202 261 3419 | +1 202 261 3333



Mina Miljevic focuses her practice on corporate and securities matters.

Ms. Miljevic was a Dechert summer associate in 2015. Prior to joining Dechert, Ms. Miljevic was a legal intern in the Department of Defense. She also served as a summer law clerk at the Miami-Dade County Attorney’s Office.

  • University of Pennsylvania, B.A., 2013, magna cum laude
  • Georgetown University Law Center, J.D., 2016, Global Law Scholar; Law Fellow; Senior Notes Editor of the Georgetown Journal of International Law; Social Enterprise & Nonprofit Law Clinic
  • District of Columbia
  • Ferring Pharmaceuticals, a multinational pharmaceutical company, in its 2019 joint investment with Blackstone Life Sciences of over US$570 million in FerGene’s nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy in late stage development for patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).
  • BioAtla, a global clinical stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, in its worldwide collaboration with BeiGene, a commercial-stage biopharmaceutical company, for the development and commercialization of CAB-CTLA-4.
  • Morphic Therapeutic, a biotechnology company, in its partnership with AbbVie, a research-based global biopharmaceutical company, in a research and development collaboration designed to advance a number of Morphic's oral integrin therapeutics for fibrosis-related indications.
  • Laguna Dairy, S.A. de C.V., a multinational fresh fluid dairy processor based in Mexico, in the sale of Borden to ACON Investments, LLC via an equity recapitalization. 
  • English
  • Serbian